These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 25113756)

  • 1. Phase I dose-escalation study of LCL161, an oral inhibitor of apoptosis proteins inhibitor, in patients with advanced solid tumors.
    Infante JR; Dees EC; Olszanski AJ; Dhuria SV; Sen S; Cameron S; Cohen RB
    J Clin Oncol; 2014 Oct; 32(28):3103-10. PubMed ID: 25113756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors.
    Heath EI; Bible K; Martell RE; Adelman DC; Lorusso PM
    Invest New Drugs; 2008 Feb; 26(1):59-65. PubMed ID: 17938863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I study of LCL161, a novel oral pan-inhibitor of apoptosis protein (IAP) antagonist, in Japanese patients with advanced solid tumors.
    Morita S; Minami H; Mitsuma A; Toyoda M; Kiyota N; Ando Y
    Asia Pac J Clin Oncol; 2022 Oct; 18(5):e427-e434. PubMed ID: 35098674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors.
    Edelman G; Rodon J; Lager J; Castell C; Jiang J; Van Allen EM; Wagle N; Lindeman NI; Sholl LM; Shapiro GI
    Oncologist; 2018 Apr; 23(4):401-e38. PubMed ID: 29593099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors.
    Hong DS; Bowles DW; Falchook GS; Messersmith WA; George GC; O'Bryant CL; Vo AC; Klucher K; Herbst RS; Eckhardt SG; Peterson S; Hausman DF; Kurzrock R; Jimeno A
    Clin Cancer Res; 2012 Aug; 18(15):4173-82. PubMed ID: 22693357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies.
    Spreafico A; Delord JP; De Mattos-Arruda L; Berge Y; Rodon J; Cottura E; Bedard PL; Akimov M; Lu H; Pain S; Kaag A; Siu LL; Cortes J
    Br J Cancer; 2015 Feb; 112(4):650-9. PubMed ID: 25625276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations.
    Dees EC; Cohen RB; von Mehren M; Stinchcombe TE; Liu H; Venkatakrishnan K; Manfredi M; Fingert H; Burris HA; Infante JR
    Clin Cancer Res; 2012 Sep; 18(17):4775-84. PubMed ID: 22767670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors.
    Markman B; Tabernero J; Krop I; Shapiro GI; Siu L; Chen LC; Mita M; Melendez Cuero M; Stutvoet S; Birle D; Anak Ö; Hackl W; Baselga J
    Ann Oncol; 2012 Sep; 23(9):2399-2408. PubMed ID: 22357447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours.
    de Jonge M; de Weger VA; Dickson MA; Langenberg M; Le Cesne A; Wagner AJ; Hsu K; Zheng W; Macé S; Tuffal G; Thomas K; Schellens JH
    Eur J Cancer; 2017 May; 76():144-151. PubMed ID: 28324749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma.
    Amaravadi RK; Schilder RJ; Martin LP; Levin M; Graham MA; Weng DE; Adjei AA
    Mol Cancer Ther; 2015 Nov; 14(11):2569-75. PubMed ID: 26333381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors.
    Oh DY; Lee SH; Han SW; Kim MJ; Kim TM; Kim TY; Heo DS; Yuasa M; Yanagihara Y; Bang YJ
    Cancer Res Treat; 2015 Oct; 47(4):607-15. PubMed ID: 25715763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors.
    Infante JR; Mendelson DS; Burris HA; Bendell JC; Tolcher AW; Gordon MS; Gillenwater HH; Arastu-Kapur S; Wong HL; Papadopoulos KP
    Invest New Drugs; 2016 Apr; 34(2):216-24. PubMed ID: 26924128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid tumors.
    Bendell JC; Patel MR; Infante JR; Kurkjian CD; Jones SF; Pant S; Burris HA; Moreno O; Esquibel V; Levin W; Moore KN
    Cancer; 2015 Apr; 121(7):1056-63. PubMed ID: 25411085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer.
    Flaherty KT; Lorusso PM; Demichele A; Abramson VG; Courtney R; Randolph SS; Shaik MN; Wilner KD; O'Dwyer PJ; Schwartz GK
    Clin Cancer Res; 2012 Jan; 18(2):568-76. PubMed ID: 22090362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.
    Schuler M; Cho BC; Sayehli CM; Navarro A; Soo RA; Richly H; Cassier PA; Tai D; Penel N; Nogova L; Park SH; Schostak M; Gajate P; Cathomas R; Rajagopalan P; Grevel J; Bender S; Boix O; Nogai H; Ocker M; Ellinghaus P; Joerger M
    Lancet Oncol; 2019 Oct; 20(10):1454-1466. PubMed ID: 31405822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of dasatinib (BMS-354825) in Japanese patients with solid tumors.
    Takahashi S; Miyazaki M; Okamoto I; Ito Y; Ueda K; Seriu T; Nakagawa K; Hatake K
    Cancer Sci; 2011 Nov; 102(11):2058-64. PubMed ID: 21781226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors.
    Smith DC; Chugh R; Patnaik A; Papadopoulos KP; Wang M; Kapoun AM; Xu L; Dupont J; Stagg RJ; Tolcher A
    Invest New Drugs; 2019 Aug; 37(4):722-730. PubMed ID: 30591982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer.
    Dy GK; Thomas JP; Wilding G; Bruzek L; Mandrekar S; Erlichman C; Alberti D; Binger K; Pitot HC; Alberts SR; Hanson LJ; Marnocha R; Tutsch K; Kaufmann SH; Adjei AA
    Clin Cancer Res; 2005 May; 11(9):3410-6. PubMed ID: 15867242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours.
    Jamieson D; Griffin MJ; Sludden J; Drew Y; Cresti N; Swales K; Merriman M; Allen R; Bevan P; Buerkle M; Mala C; Coyle V; Rodgers L; Dean E; Greystoke A; Banerji U; Wilson RH; Evans TR; Anthoney A; Ranson M; Boddy AV; Plummer R
    Eur J Cancer; 2016 Nov; 68():1-10. PubMed ID: 27693888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I safety and pharmacokinetic dose-escalation study of pilaralisib polymorph E, a phosphoinositide 3-kinase inhibitor in tablet formulation, in patients with solid tumors or lymphoma.
    Bechter OE; Dumez H; Costermans J; Punie K; Hsu K; Dedieu JF; Ghuysen AF; Francesconi E; Sharma J; Liu L; Schöffski P
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):83-90. PubMed ID: 27169794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.